A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

NCT05951959 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Mantle Cell Lymphoma (MCL)

Interventions

DRUG: Acalabrutinib
DRUG: Venetoclax
DRUG: Rituximab

Sponsor

AstraZeneca